Please assess the completion status of the following clinical trial:

Trial Title: Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma (AC) or squamous cell carcinoma of the esophagus~  * AC of the gastroesophageal junction allowed~* Tumor must be considered surgically resectable (T1-3, NX)~  * No early-stage cancer (T1, N0)~* The following lymph node (LN) criteria are considered acceptable:~  * Regional thoracic LN metastases (N1)~ * LN metastases levels 15 to 20 measured as ≤ 1.5 cm by CT scan~ * Supraclavicular LN not palpable on clinical examination measured as ≤ 1.5 cm by CT scan~* No distant metastases (M0)~PATIENT CHARACTERISTICS:~* Platelet count ≥ 100,000/mm\^3~* Absolute neutrophil count ≥ 1,500/mm\^3~* Hemoglobin ≥ 9.0 g/dL~* Creatinine clearance ≥ 50 mL/min~* Creatinine serum level ≤ CTC grade 2~* Bilirubin ≤ 2 times upper limit of normal (ULN)~* AST \< 3 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after completion of study treatment~* No known severe hypersensitivity to gefitinib or any of its excipients~* No evidence (except asymptomatic chronic stable radiographic changes) of clinically active interstitial lung disease~* No pulmonary fibrosis, Gilbert's disease, uncontrolled diabetes mellitus, or unstable angina~* No New York Heart Association class III or IV heart disease~* No other concurrent malignancies or malignancies diagnosed within the past 5 years except basal cell carcinoma or carcinoma in situ of the cervix~* No serious active or uncontrolled infection, systemic disease, psychiatric illness, or other medical condition that would preclude study participation~* No evidence of any significant clinical disorder or laboratory finding that would preclude study participation~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy or radiotherapy for esophageal cancer~* No prior radiotherapy that would overlap the study treatment fields~* Recovered from prior major surgery~* No nonapproved or investigational drugs within the past 30 days~* No concurrent phenytoin, carbamazepine, barbiturates, rifampin, phenobarbital, or Hypericum perforatum (St. John's wort)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).